Organic Active Ingredients TRIZ Cases

An ester-linked cyclodextrin carrier boosts water solubility and therapeutic efficacy of arteannuinoids, overcoming rapid elimination in cancer treatment.

High-affinity antibody molecules inhibit CD73 enzymatic activity, reducing adenosine production and enhancing T cell proliferation in cancer therapy.

Carboxyl-indole inhibitors restore carbapenem efficacy against resistant bacteria by blocking metallo-beta-lactamase active sites.

PAI-1 inhibitors treat ineffective dermatological conditions by targeting specific molecular pathways.

4'-vinyl nucleoside derivatives inhibit respiratory syncytial virus polymerase, addressing insufficient treatment effectiveness of conventional analogues.

Halimide and plinabulin address drug-resistant epilepsy by modifying chemical structures to reduce adverse effects while maintaining antiseizure efficacy.

Modified fumarate derivatives inhibit disease progression by reducing oxidative-nitrosative species, addressing insufficient therapeutic effectiveness.

Allosteric modulation of mGlu5 receptors improves oral bioavailability and reduces adverse effects compared to orthosteric antagonists.

Crystalline potassium salt of letermovir forms via neutralization in dialkyl ether and alcohol mixtures.

Azaphilone compounds activate natural killer cells to overcome acquired resistance in cancer immunotherapy.

siRNA-lipid particles bypass small molecule resistance by silencing Eg5, EGFR, and XIAP genes to inhibit proliferation.

Lipid carrier nanoparticles resolve respiratory distribution bottlenecks by enhancing solubility and enabling sustained release of antiviral drugs.

Segmented fused bicyclic compounds target NUAK1 or NUAK2 selectively, resolving limited treatment options for kinase-mediated diseases.

Segmented drug conjugates reduce systemic toxicity by delivering cytotoxic agents to cancer cells through selective Hsp90 binding.

Glycyrrhetinic acid derivatives inhibit HSD2 to promote potassium excretion, avoiding gastrointestinal side effects of current treatments.

Plasma protein carriers transport indole-3-propionic acid across the blood-brain barrier, solving delivery complexity without synthetic systems.

A chimeric single-stranded oligonucleotide couples DNA and RNA segments via a degradable linker to form a stable hybrid structure.

Replacing unstable heparin with stable citrate in peritoneal dialysis fluid maintains osmotic force and solute clearance without inflammation.

Intranasal FLAP inhibitors cross the blood-brain barrier to reduce leukotriene-mediated neuroinflammation and prevent secondary brain damage.

Polar substituents on steroid analogues increase water solubility, improving bioavailability for treating traumatic brain injury.

Segmenting GR antagonist therapy with conventional treatments overcomes resistance mechanisms while reducing toxicities.

Meglumine stabilizes macrocyclic lactones in liquid antiparasitic compositions.

Separating enantiomers eliminates unwanted sigma 2 binding, resolving specificity trade-offs in Alzheimer's treatments.

Enteric coating isolates tetrahydrofolic acid from oxygen and moisture, maintaining stability while ensuring fast release of estrogen and progestogen.

Strictly limiting glucose and mannose in sugar alcohols prevents Maillard reaction coloring and aggregation during storage.

SKP2 expression analysis predicts MDM2 antagonist sensitivity, avoiding ineffective treatments and reducing diagnostic complexity.

Novel indole derivatives inhibit sodium-dependent glucose transporters to promote urinary glucose excretion.

Glutathione modification of rapamycin derivatives overcomes poor in vivo stability and low bioavailability, enabling effective therapeutic delivery.

LMNA-targeted antisense oligonucleotides reduce progerin expression by modulating aberrant splicing of LMNA pre-mRNA.

Segmented microbubble and nanoparticle carriers accumulate in lung tissue to deliver medical components, reducing toxicity to healthy tissues.

Combining interleukin-1 inhibitors with chemotherapy agents to reduce cachexia severity in pancreatic cancer patients.

Compound I stimulates soluble guanylate cyclase to modulate cGMP levels, reducing fasting blood glucose and insulin resistance in metabolic syndrome.

Tris(hydroxymethyl)aminomethane salts of tris-ODAAD1 resist rapid proteolysis to enhance oral bioavailability and glycemic control.

Specific chemical substitutions at defined molecular positions reduce systemic toxicity while maintaining antitumor efficacy.

Combines phenylephrine and ketorolac in an intraocular irrigation solution to maintain pupil diameter during surgery.

Novel enteropeptidase inhibiting compound reduces gastrointestinal protein and lipid absorption.

Optimized molecular structures enhance blood-brain barrier penetration and plasma circulation time while suppressing type I interferon expression.

PVA-MCC co-mixture enables direct compression of pharmaceutical tablets without granulation.

Replacing lipid emulsions with benzyl alcohol resolves solubility stability trade-offs, enabling efficient sterilization of the aqueous formulation.

Administering mifepristone alongside PD-1 or CTLA-4 antagonists overcomes pancreatic ductal adenocarcinoma resistance to reduce tumor weight by 60%.

Replacing complex cyclic dinucleotides with a fluorinated benzothiophene scaffold improves metabolic stability and synthesis ease for tumor treatment.

Copolymerizing antimicrobial monomers into the polymer bulk prevents infection without metal ion toxicity.

Cell-permeant protease inhibitor compounds target the SARS-CoV-2 main protease to block viral replication.

Sulfonamide derivatives replace unstable peptides with stable small molecules, reducing systemic side effects while treating ocular inflammation.

A hyaluronic acid conjugate delivers aminobisphosphonates via a spacer bond that triggers gel formation upon calcium exposure.

Specific antineoplaston ratios improve survival in pediatric leptomeningeal disease while reducing severe adverse effects.

An epidithiodioxopiperazine compound with an intramolecular disulfide bond blocks pulmonary arterial wall thickening.

Electrochemically etched porous silicon nanostructures separate and detect target analytes through optical reflectivity changes.

Combining durvalumab with gemcitabine and cisplatin enhances anti-tumor immunity in advanced biliary tract cancer treatment.